<?xml version='1.0' encoding='utf-8'?>
<document id="19889612"><sentence text="A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies."><entity charOffset="84-94" id="DDI-PubMed.19889612.s1.e0" text="paclitaxel" /><entity charOffset="99-110" id="DDI-PubMed.19889612.s1.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.19889612.s1.e0" e2="DDI-PubMed.19889612.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19889612.s1.e0" e2="DDI-PubMed.19889612.s1.e1" /></sentence><sentence text="The purpose of the phase I dose-escalation study was to evaluate the maximum tolerated dose (MTD) of BIBF 1120, an oral triple angiokinase inhibitor of vascular endothelial growth factor, platelet derived growth factor and fibroblast growth factor receptors, combined with paclitaxel and carboplatin"><entity charOffset="273-283" id="DDI-PubMed.19889612.s2.e0" text="paclitaxel" /><entity charOffset="288-299" id="DDI-PubMed.19889612.s2.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.19889612.s2.e0" e2="DDI-PubMed.19889612.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19889612.s2.e0" e2="DDI-PubMed.19889612.s2.e1" /></sentence><sentence text="" /><sentence text="Patients with advanced gynecological malignancies received BIBF 1120 twice-daily (b" /><sentence text="i" /><sentence text="d" /><sentence text=") continuously at 100, 150, 200 or 250 mg, combined with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve 5 min"><entity charOffset="57-67" id="DDI-PubMed.19889612.s7.e0" text="paclitaxel" /><entity charOffset="86-97" id="DDI-PubMed.19889612.s7.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.19889612.s7.e0" e2="DDI-PubMed.19889612.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19889612.s7.e0" e2="DDI-PubMed.19889612.s7.e1" /></sentence><sentence text="mg/ml) every 3 weeks" /><sentence text=" The MTD, safety, pharmacokinetics (PK) and clinical activity were evaluated" /><sentence text="" /><sentence text="Twenty-two patients were treated" /><sentence text=" Three experienced dose-limiting toxic effects in the first treatment cycle: 1 of 13 at 200 mg b" /><sentence text="i" /><sentence text="d" /><sentence text=" BIBF 1120 [diarrhea, common terminology criteria for adverse events (CTCAE) grade 3]; two of two at 250 mg b" /><sentence text="i" /><sentence text="d" /><sentence text=" BIBF 1120 (elevated alanine aminotransferase and aspartate aminotransferase, CTCAE grade 3/4)"><entity charOffset="21-28" id="DDI-PubMed.19889612.s18.e0" text="alanine" /><entity charOffset="50-59" id="DDI-PubMed.19889612.s18.e1" text="aspartate" /><pair ddi="false" e1="DDI-PubMed.19889612.s18.e0" e2="DDI-PubMed.19889612.s18.e0" /><pair ddi="false" e1="DDI-PubMed.19889612.s18.e0" e2="DDI-PubMed.19889612.s18.e1" /></sentence><sentence text=" The MTD was defined as 200 mg b" /><sentence text="i" /><sentence text="d" /><sentence text=" Principal adverse events were gastrointestinal disorders" /><sentence text=" No clinically relevant drug-drug interaction was observed after 20 days treatment with 200 mg b" /><sentence text="i" /><sentence text="d" /><sentence text=" BIBF 1120 on the PK of paclitaxel or carboplatin and vice versa"><entity charOffset="24-34" id="DDI-PubMed.19889612.s26.e0" text="paclitaxel" /><entity charOffset="38-49" id="DDI-PubMed.19889612.s26.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.19889612.s26.e0" e2="DDI-PubMed.19889612.s26.e0" /><pair ddi="false" e1="DDI-PubMed.19889612.s26.e0" e2="DDI-PubMed.19889612.s26.e1" /></sentence><sentence text="" /><sentence text="The MTD of BIBF 1120 in a 20-day continuous dosing regimen with standard-dose paclitaxel and carboplatin was 200 mg b"><entity charOffset="78-88" id="DDI-PubMed.19889612.s28.e0" text="paclitaxel" /><entity charOffset="93-104" id="DDI-PubMed.19889612.s28.e1" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.19889612.s28.e0" e2="DDI-PubMed.19889612.s28.e0" /><pair ddi="false" e1="DDI-PubMed.19889612.s28.e0" e2="DDI-PubMed.19889612.s28.e1" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=" This combination had an acceptable safety profile and no clinically relevant drug-drug interactions" /><sentence text=" Further evaluation of this combination is warranted in this indication" /><sentence text="" /></document>